Metrics as of 10/16/2026, 12:43 PM (Berlin time), refresh in progress.
Cerus Stock
Cerus Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Vivek K. Jayaraman
- Employees
- 268
- Market cap
- $439 M
- IPO
- 31/01/1997
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's…
Cerus stock: price history
1D
+0.9%
1W
-0.9%
1M
-9.6%
6M
+13.0%
YTD
+9.7%
1Y
+42.1%
2Y
+25.6%
5Y
-63.1%
10Y
-56.3%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~54% stronger price swings than usual
Cerus stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 28/08/2026.
Ask the agents about Cerus
Analyst assessment of Cerus
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 01/05/2026
Cerus stock metrics
P/E
-62.43
P/B
6.47
EV/EBITDA
176.85
RETURN ON EQUITY
-4.2%
NET MARGIN
-5.1%
DEBT/EQUITY
1.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.6%
FLOAT SHARES
190,676,708
AVG. DAILY VOLUME (30D)
1,748,040
Insider transactions (SEC)
Jensen Chrystal
Jayaraman Vivek K
Greenman William Mariner
Green Kevin Dennis
Green Kevin Dennis
Attention
Price since yesterday: +0.9%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Cerus stock
What does Cerus do?
Cerus Corporation is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Vivek K. Jayaraman, the company employs around 268 people.
The IPO was on 31/01/1997; the stock trades on NASDAQ under the ticker CERS.
What do analysts say about Cerus stock?
10 analysts rate the stock, the consensus is Buy (as of 01/05/2026).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Cerus report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 54% stronger than usual.
Does Cerus pay a dividend?
No, Cerus currently does not pay a dividend.
Which stocks are comparable to Cerus?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Cerus stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cerus against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.